The Pharmacy Times® Multiple Myeloma Resource Center is a comprehensive resource for clinical news and expert insights on issues related to cancer that forms in a type of white blood cell.
September 6th 2024
The evolving treatment landscape for multiple myeloma includes debates on the timing and effectiveness of CAR T-cell therapy and quadruple immunotherapy regimens.
Chronic Myeloid Leukemia: Navigating Drug Resistance and Optimizing Care
1.0 Credit / Hematologic Cancer, Hematology, Oncology
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
Recent Advances in BCMA-Directed Treatment in Multiple Myeloma: Insights and Application for Managed Care
1.0 Credits / Hematologic Cancer, Oncology
View More
Revolutionizing Multiple Myeloma Care: CAR T-Cell Therapy, Bispecific Antibodies, and Patient-Centered Strateg...
1.0 Credit / Oncology, Hematologic Cancer
View More
Elevating Safety and Adherence in Chronic Myeloid Leukemia Through Oncology Pharmacist Expertise
1.0 Credit / Hematologic Cancer, Oncology
View More
Navigating Chronic Lymphocytic Leukemia Therapy and Cardiovascular Comorbidities: Clinical Recommendations and...
1.0 Credit / Hematologic Cancer
View More
Balancing Innovation and Implementation: A Comprehensive Approach to CAR T, Bispecific Antibodies, and Operati...
1.0 Credit / Hematologic Cancer, Oncology
View More
Optimizing Bispecific Antibody Utilization in Non-Hodgkin Lymphoma: Addressing Challenges in Community-Based C...
1.0 Credit / Hematologic Cancer, Oncology
View More
Enhancing Bruton Tyrosine Kinase Inhibitor Outcomes in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma: ...
1.0 Credit / Hematologic Cancer
View More
Optimizing JAK Inhibitor Therapy for Myelofibrosis: Insights for Oncology Pharmacists
1.0 Credit / Hematologic Cancer, Oncology
View More
New Frontiers in the Treatment of Lower-Risk Myelodysplastic Syndromes: Bridging Clinical Innovation and Pract...
1.0 Credit / Hematologic Cancer, Oncology
View More
Finding Balance Between Advancement and Application: A Guide for Community Oncology Pharmacists on CAR T-Cell ...
0.75 Credit / Oncology, Hematologic Cancer
View More
Addressing the Gaps and Clinical Challenges in Chronic Lymphocytic Leukemia: Updates and Strategies for Manage...
1.5 Credits / Hematology, Hematologic Cancer, Oncology
View More
Keeping Pace With New Developments in Multiple Myeloma: Updates and Strategies to Optimize Bispecific Antibodi...
1.5 Credits / Oncology, Hematology, Hematologic Cancer
View More
Navigating Long-Term Toxicities of CAR T-Cell Therapy: Educational Insights for Oncology Pharmacists
1.25 Credits / Oncology, Hematologic Cancer
View More
Overcoming Disparities in Multiple Myeloma Treatment: Empowering Pharmacists to Drive Change
1.0 Credit / Health Equity, Diversity & Inclusion, Hematologic Cancer, Hematology, Oncology
View More
FDA Approves Selinexor Combination Treatment for Certain Patients With Multiple Myeloma
December 19th 2020Selinexor (Xpovio; Karyopharm Therapeutics Inc.) in combination with bortezomib (Velcade; Takeda) and dexamethasone was approved for the treatment of adult patients with multiple myeloma who have received at least 1 prior therapy.
Read More
Preliminary Results of Ciltacabtagene Autoleucel in Treating Relapsed/Refractory Multiple Myeloma
December 10th 2020Data from a preliminary phase 1b/2 study demonstrated a single low-dose infusion of ciltacabtagene autoleucel resulted in early, deep, and durable responses in heavily pretreated patients with multiple myeloma.
Read More
Using Belantamab Mafodotin and Pomalidomide in the Treatment of Relapsed/Refractory Multiple Myeloma
December 9th 2020Suzanne Trudel, MD, MSC, FRCPC, of the University of Toronto and the Princess Margaret Cancer Centre in Toronto, discusses what belantamab mafodotin and pomalidomide are, and how they work together to treat relapsed/refractory multiple myeloma.
Watch